Hospital

The new, standardized, ready-to-use formulation of phenylephrine HCl can help reduce medication errors and improve patient safety.

At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.

According to investigators at the National Institutes of Health, a single dose of highly diluted VSV-Ebola virus (EBOV) vaccine is still protective against the disease.

Top news of the day from across the health care landscape.

Four pharmaceutical distributors have agreed to settle federal litigation related to the ongoing opioid epidemic for a collective $260 million, less than a day before a federal trial was set to begin in Ohio.

Limited supply of chemotherapy agent that treats several pediatric cancers may lead to rationing of doses.

Pending results of the California Practice Standards and Jurisprudence Exam (CPJE) have been invalidated for 1400 applicants that recently took the test, due to a cheating issue.

Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic of Janssen's Zytiga tablets, 250 mg.1

Nine widely-used medications have experienced substantial price growth since 2016, adding $5.1 billion to overall drug spending.

The full-day meeting will feature recognized experts sharing the latest clinical data in oncology, while exploring best practices and management strategies.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.

Top news of the day from across the health care landscape.

Today is National Pharmacy Technician Day, and pharmacists are sharing how valuable technicians are to them.

In the wake of California’s drug transparency law, an analysis by state health officials on pricing trends found that drug companies raised the whole acquisition cost dramatically for many drugs.

The Rite Aid Foundation is awarding $2.3 million to Children’s Miracle Network Hospitals through its KidCents Grant Program.

To date, the FDA has granted rivaroxaban 8 indications, 6 of which are specifically for the treatment, prevention, and reduction in the risk of recurrence of venous thromboemolism across a wide range of patient populations.

A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.

Top news of the week from Specialty Pharmacy Times.

This article is the third in a series on difficult to pronounce drug names.

Officials from the FDA have allowed marketing of a rapid diagnostic test (RDT) to help detect Ebola virus antigens in the bloodstream from certain living individuals and samples from recently deceased individuals suspected to have Ebola.

Top news of the day from across the health care landscape.

A recent study has revealed that just under half of the US population fears random mass shootings and terrorist attacks.

A webinar held by Trellis Rx discussed actionable ways to establish a successful clinic-based specialty pharmacy approach.

NAMI Basics OnDemand is an adaptation of the in-person NAMI Basics, a free, 6-session education program for parents, caregivers, and other family who provide care for adolescents aged 22 years or younger who are experiencing mental health symptoms.

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.

A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.

The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.

The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.